Last reviewed · How we verify
Calcipotriene plus betamethasone dipropionate ointment
Calcipotriene plus betamethasone dipropionate ointment works by reducing inflammation and slowing the growth of skin cells in the treatment of psoriasis.
Calcipotriene plus betamethasone dipropionate ointment works by reducing inflammation and slowing the growth of skin cells in the treatment of psoriasis. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | Calcipotriene plus betamethasone dipropionate ointment |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Topical corticosteroid and vitamin D analog |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Calcipotriene is a vitamin D analog that inhibits the growth of skin cells, while betamethasone dipropionate is a corticosteroid that reduces inflammation. Together, they help to slow the growth of skin cells and reduce inflammation in the treatment of psoriasis.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Skin burning sensation
- Skin irritation
- Skin redness
Key clinical trials
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
- The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris (PHASE1, PHASE2)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris (PHASE3)
- LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (PHASE3)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: